Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Michele B. Kaufman, PharmD, BCGP

Michele B. Kaufman, PharmD, BCGP, is a freelance medical writer and editor. She is also a pharmacist at New York Presbyterian Hospital–Lower Manhattan campus. She has been a past guest lecturer at Touro College of Pharmacy in New York City for the Medical Writing elective. Dr Kaufman is a member of the New York City Society of Health-Systems Pharmacy, the New York State Council of Health-System Pharmacists, the Academy of Managed Care Pharmacy (AMCP)—Northeast Region Affiliate Chapter, the American Society of Consultant Pharmacists and the Empire State-Metropolitan NY Chapter of the American Medical Writers Association. She received her BS in Pharmacy from the University of Rhode Island (URI) College of Pharmacy and her Doctor of Pharmacy degree from Massachusetts College of Pharmacy and Allied Health Sciences in Boston. She also completed a Drug Information Fellowship at the URI Drug Information Center/Roger Williams Medical Center in Providence, R.I. Dr Kaufman is a registered pharmacist and is a Board-Certified Geriatric Pharmacist.

Articles by Michele B. Kaufman, PharmD, BCGP

U.S. & Europe Evaluate Abaloparatide Injection & Europe Approves Marketing Baricitinib for RA

Michele B. Kaufman, PharmD, BCGP  |  April 11, 2017

Injectable abaloparatide is being evaluated in the U.S. and Europe to treat postmenopausal women with osteoporosis…

Sirukumab Promising for RA

Michele B. Kaufman, PharmD, BCGP  |  April 4, 2017

In a clinical trial, RA patients on sirukumab experienced decreased disease activity and improved physical function…

Ustekinumab Has Longer Efficacy Duration than TNFIs for Plaque Psoriasis

Michele B. Kaufman, PharmD, BCGP  |  March 28, 2017

When compared with TNFIs, ustekinumab demonstrated a longer drug survival rate in patients with severe plaque psoriasis…

Factors that Influence Biologic Therapy Choices for Patients with Rheumatoid Arthritis

Michele B. Kaufman, PharmD, BCGP  |  March 20, 2017

Recent research analyzed factors influencing the selection of the first-line biologic medications and the real-life factors that lead to switching from those medications to other biologics in treating rheumatoid arthritis (RA). The study compared the use of abatacept and tocilizumab with a tumor necrosis factor alpha inhibitor (TNFi).1,2 Participants were enrolled in the Lombardy Rheumatology…

Brodalumab Approved for Plaque Psoriasis

Michele B. Kaufman, PharmD, BCGP  |  March 9, 2017

Brodalumab has received FDA approval for treating plaque psoriasis in adults, with a Boxed Warning against prescribing it for patients with a history of suicidal thoughts or behavior…

Baricitinib May Exhibit Better Efficacy Than Adalimumab for RA

Michele B. Kaufman, PharmD, BCGP  |  March 7, 2017

In a recent study, baricitinib proved more effective than adalimumab in treating adults with RA through 52 weeks…

Certolizumab Pegol Promising for Plaque Psoriasis in Phase 3 Trial

Michele B. Kaufman, PharmD, BCGP  |  March 1, 2017

Certolizumab pegol has proved safe and effective for treating patients with plaque psoriasis in a Phase 3 clinical trial…

FDA Considers Tocilizumab for GCA & Piclidenoson Enters Phase 3 Trial for RA, Psoriasis

Michele B. Kaufman, PharmD, BCGP  |  February 27, 2017

The FDA is considering a supplemental biologics license application for tocilizumab to treat giant cell arteritis…

Physician’s Choice: Factors That Influence First- & Second-Line Biologic Therapy in RA Patients

Michele B. Kaufman, PharmD, BCGP  |  February 20, 2017

In patients with RA, age and higher rates of comorbidity are influential in selecting and changing treatments…

Insights into Drug-Related Interactions in Older Adults

Michele B. Kaufman, PharmD, BCGP  |  February 9, 2017

A study showed that prior hospitalization and the use of multiple medications are risk factors for drug and drug–disease interactions…

  • « Previous Page
  • 1
  • …
  • 27
  • 28
  • 29
  • 30
  • 31
  • …
  • 45
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences